Please login to the form below

Not currently logged in
Email:
Password:

Teva sues Apotex to block generic Coreg

Israel-headquartered Teva Pharmaceutical has sued Canada-based Apotex to prevent the generic rival from selling a copy of GlaxoSmithKline's (GSK) antihypertensive drug, Coreg (carvedilol).

Israel-headquartered Teva Pharmaceutical has sued Canada-based Apotex to prevent the generic rival from selling a copy of GlaxoSmithKline's (GSK) antihypertensive drug, Coreg (carvedilol).

Apotex, Teva and other generic-drug makers won FDA approval to sell the generic version on 5 September 2007. Teva says that it owns four patents which cover various forms and processes to make carvedilol.

To sell carvedilol, says Teva, Apotex might have to purchase the compound made using the patented process. Apotex has not supplied the necessary data required to rule whether the generic uses patented processes or not. Teva has filed for a court order to prevent patent infringement by Apotex.

For H1 FY07, Coreg posted sales of USD 854m and analysts say that the annual generic market for carvedilol could be worth as much as USD 50m.

30th September 2008

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
COUCH Health

We are a patient engagement agency committed to making clinical study experiences human. By guiding organisations in making everything they...

Latest intelligence

white house
Eliminating pharmaceutical rebates, is this déjà vu?
By Andrew Parece and Matthew Majewski...
Patients are ready to embrace decentralised clinical trials, are you?
Traditional clinical trial designs simply can’t withstand the impact of COVID-19. While before the pandemic, some in clinical research were beginning to adopt virtual components, the move towards designing hybrid...
Has the pandemic opened up a future of accelerated diagnosis and better care for rare disease patients?
The challenge with rare disease is in the name – it's rare, so awareness is limited and diagnosis hindered. Could a more virtual existence change this? A Medical Affairs viewpoint...

Infographics